Ana Svensson

Search
Speakers

Dr Ana Svensson is Senior Medical Director at Novo Nordisk Oceania. Ana has over 25 years of experience in medical and pharmaceutical roles and has held senior medical affairs positions, working across Europe, Japan, USA and Australia throughout her career. Throughout her career, Ana has covered a broad range of drug development in various therapeutic areas including cardiometabolic, immunology, nephrology and oncology, and has had experience as medical practitioner and across clinical research and medical affairs.

Abstracts this author is presenting:

Efficacy, observer-reported outcomes and safety of once-weekly somapacitan in children with growth hormone deficiency (GHD): 4-year results from the REAL 3 trial — ANZSPED (née APEG) Poster Listing: Scientific Abstract
Once-weekly somapacitan versus daily growth hormone (GH) in children with GH deficiency (GHD): the randomised phase 3 REAL 4 trial — ANZSPED (née APEG) Poster Listing: Scientific Abstract
Growth hormone (GH) replacement therapy (GHRT) in patients with adult GH deficiency (AGHD) aged ≥60 years: data from NordiNet^® IOS and the ANSWER Program — ESA/NZSE Poster Listing: Clinical

Ana Svensson ESA-SRB-APEG-NZSE 2022

Ana Svensson

Abstracts this author is presenting: